Lyka Labs Limited has informed the Exchange about General Updates

Nclt Scheme FiledStrategic Transactions View source PDF Explain this filing

LYKALABS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-2.3%Reaction day

₹118.75

prior close

₹115.76

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-0.3%-2.0% vs market

Pharmaceuticals peers, median of 148sector-0.5%-1.9% vs sector

On the reaction day the stock moved 2.0 pts less than Nifty Microcap 250 and 1.9 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.2

10m

-0.2

15m

-0.0

30m

+0.2

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-2.3-0.3-2.0-0.5-1.9

Next day

-3.8-0.0-3.8-0.5-3.3

-3.1-1.0-2.0-1.8-1.3

-3.7-1.3-2.4-2.6-1.2

-5.6-3.1-2.5-4.0-1.6

-4.8-2.8-2.0-3.6-1.2

-4.4-2.1-2.3-3.0-1.4

15d

-4.5+1.6-6.1-0.1-4.5

-6.6+1.4-8.1+0.3-6.9

-14.9-2.7-12.3-4.4-10.6

-17.6+0.1-17.7-3.1-14.5

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 148Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Lyka Labs Limited informed the exchanges that the NCLT Ahmedabad Bench hearing on the Scheme of Amalgamation between Lyka Exports Limited (Transferor Company) and Lyka Labs Limited (Transferee Company) was held on June 12, 2025. The case was adjourned and is now listed for further hearing on July 10, 2025. The amalgamation is being processed under Sections 230-232 of the Companies Act, 2013. No swap ratio or financial details were disclosed in this update.

Likely market impact

This is a procedural update with no immediate change for shareholders. The amalgamation remains in progress, and investors should watch the July 10, 2025 hearing for the next substantive update on the scheme's approval.